features: Lymphoma

Epcoritamab receives FDA approval for patients with R/R DLBCL and HGBCL

On May 19, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of epcoritamab monotherapy…

Read More

FDA approves polatuzumab vedotin plus R-CHP for patients with previously untreated DLBCL

On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved the use of polatuzumab vedotin with rituximab, cyclophosphamide,…

Read More

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

Read More

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

Read More

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Read More

ASH press briefing rundown: optimizing pediatric care

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Read More

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Read More

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

Read More

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

Read More

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Read More

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Read More

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Read More

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Read More

BTK inhibitors for B-cell malignancies: managing and improving class-driven adverse events

Bruton’s tyrosine kinase (BTK) inhibitors fulfill an increasingly important role in the treatment of patients with B-cell malignancies including chronic…

Read More

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Read More

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Read More

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals